drugset
drugset / Trial / NCT06585514

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

NCT06585514 ↗

Phase 1/2 Recruiting 18 enrolled Beijing GoBroad Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).

Timeline

Start
2024-10-17
Primary completion
2026-09-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19 CAR-T cells Cell therapy — —

Indications

lupus nephritis systemic lupus erythematosus